摘要:
Composition for the treatment of infant or adult respiratory distress syndrome (IRDS and ARDS) contains N-(3,5-dichloropyrid-4-yl)-3- cyclopropylmethoxy-4- difluoromethoxybenzamide (II) (and/or its salts) and a lung surfactant.
摘要:
The invention relates to the combined use of the PDE4 inhibitor N- (3,5-dichloropyrid-4-yl)- 3-cyclopropylmethoxy- 4-difluoromethoxybenzamide, its pharmacologically tolerable salts or its N- oxide with a PDE3 inhibitor for the treatment of certain disease conditions such as, for example, acute or chronic obstructions of the bronchi.
摘要:
The disclosure concerns novel polypeptides of formula (I) with lung activity properties. These polypeptides can be produced in large quantities and in highly pure form and are as effective as natural lung surfactants. They can be used in the production of pharmaceutical composition for the treatment of respiratory distress syndrome in premature babies and adults. In said formula (I): A represents H or Phe, B represents Phe or Trp, and C represents Ile, Leu or Ser.
摘要:
Novel compositions for the treatment of IRDS and ARDS are indicated which contain a selective COX-2 inhibitor, and/or a pharmaceutically acceptable salt thereof and lung surfactant.
摘要:
The invention relates to compounds of formula (I), wherein A, B, D, E, R1, R2, R3 and Y have the meanings cited in the description, said compounds being new effective bronchial therapeutic agents.
摘要:
Compounds of formula (I) in which R is a phenyl radical substituted by R , where R is a tetrazole-5-yl radical optionally substituted by a radical R , are novel efficacious PDE3/4 inhibitors.
摘要:
Novel compositions are disclosed for the treatment of IRDS and ARDS, containing at least one glucocorticosteroid and a pulmonary surfactant. The duration of treatment and the mortality associated with these syndromes can be significantly reduced with the proposed novel compositions.
摘要:
Compounds of formula (I), where R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings given in the description, are new active bronchial therapeutic agents.